Cargando…
Reduction of exercise capacity in sarcoidosis in relation to disease severity
INTRODUCTION: Pulmonary function tests (PFTs) do not always predict functional limitations during exercise in sarcoidosis. Cardiopulmonary exercise testing (CPET) may facilitate the recognition of exercise intolerance in these patients. AIM: As relevant data in sarcoid patients are limited, the aim...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547650/ https://www.ncbi.nlm.nih.gov/pubmed/26316723 http://dx.doi.org/10.2147/PPA.S86465 |
_version_ | 1782387089853120512 |
---|---|
author | Kallianos, Anastasios Zarogoulidis, Paul Ampatzoglou, Fotini Trakada, Georgia Gialafos, Elias Pitsiou, Georgia Pataka, Athanasia Veletza, Lemonia Zarogoulidis, Konstantinos Hohenforst-Schmidt, Wolfgang Petridis, Dimitris Kioumis, Ioannis Rapti, Aggeliki |
author_facet | Kallianos, Anastasios Zarogoulidis, Paul Ampatzoglou, Fotini Trakada, Georgia Gialafos, Elias Pitsiou, Georgia Pataka, Athanasia Veletza, Lemonia Zarogoulidis, Konstantinos Hohenforst-Schmidt, Wolfgang Petridis, Dimitris Kioumis, Ioannis Rapti, Aggeliki |
author_sort | Kallianos, Anastasios |
collection | PubMed |
description | INTRODUCTION: Pulmonary function tests (PFTs) do not always predict functional limitations during exercise in sarcoidosis. Cardiopulmonary exercise testing (CPET) may facilitate the recognition of exercise intolerance in these patients. AIM: As relevant data in sarcoid patients are limited, the aim of the study reported here was to assess exercise capacity impairment during a maximal CPET and to evaluate potential correlations with PFT measurements and radiological stages of the disease. METHOD: A total of 83 sarcoid patients consecutively referred for evaluation of exertional dyspnea over a 3-year period were studied retrospectively with PFTs, including spirometry, diffusing capacity of the lung for carbon monoxide (DLCO) and lung volumes, and CPET using standard protocol. Patients were grouped according to their radiological stages: Stage I (n=43), Stages II–III (n=31), and Stage IV (n=9). RESULTS: Forced expiratory volume in 1 second, forced vital capacity, and total lung capacity were mildly impaired only in Stage IV (means ± standard deviation: 72.44±28.00, 71.33±26.70, and 59.78±21.72, respectively), while DLCO was mildly and moderately reduced in Stages II–III and IV (72.68±14.13 and 51.22±18.50, respectively) and differed significantly between all stages (I vs II–III: P=0.003, I vs IV: P=0.003, and II–III vs IV: P=0.009). Exercise capacity (as expressed by peak oxygen consumption <84% predicted) was decreased in 53% of patients (Stage I: 48%, Stages II–III: 52%, Stage IV: 78%); however, significant differences were noticed only between Stages I and IV (P=0.0025). Of note, significant correlations were found between peak oxygen consumption and DLCO (P=0.0083), minute ventilation (P<0.0001), oxygen pulse (P<0.0001), lactate threshold (P<0.0001), and peak ventilatory threshold (P<0.0001). CONCLUSION: CPET could be considered a useful tool in exercise intolerance evaluation in sarcoid patients with mild PFT abnormalities. Exercise limitation in sarcoidosis may be attributed to both ventilatory and cardiocirculatory impairment. |
format | Online Article Text |
id | pubmed-4547650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45476502015-08-27 Reduction of exercise capacity in sarcoidosis in relation to disease severity Kallianos, Anastasios Zarogoulidis, Paul Ampatzoglou, Fotini Trakada, Georgia Gialafos, Elias Pitsiou, Georgia Pataka, Athanasia Veletza, Lemonia Zarogoulidis, Konstantinos Hohenforst-Schmidt, Wolfgang Petridis, Dimitris Kioumis, Ioannis Rapti, Aggeliki Patient Prefer Adherence Original Research INTRODUCTION: Pulmonary function tests (PFTs) do not always predict functional limitations during exercise in sarcoidosis. Cardiopulmonary exercise testing (CPET) may facilitate the recognition of exercise intolerance in these patients. AIM: As relevant data in sarcoid patients are limited, the aim of the study reported here was to assess exercise capacity impairment during a maximal CPET and to evaluate potential correlations with PFT measurements and radiological stages of the disease. METHOD: A total of 83 sarcoid patients consecutively referred for evaluation of exertional dyspnea over a 3-year period were studied retrospectively with PFTs, including spirometry, diffusing capacity of the lung for carbon monoxide (DLCO) and lung volumes, and CPET using standard protocol. Patients were grouped according to their radiological stages: Stage I (n=43), Stages II–III (n=31), and Stage IV (n=9). RESULTS: Forced expiratory volume in 1 second, forced vital capacity, and total lung capacity were mildly impaired only in Stage IV (means ± standard deviation: 72.44±28.00, 71.33±26.70, and 59.78±21.72, respectively), while DLCO was mildly and moderately reduced in Stages II–III and IV (72.68±14.13 and 51.22±18.50, respectively) and differed significantly between all stages (I vs II–III: P=0.003, I vs IV: P=0.003, and II–III vs IV: P=0.009). Exercise capacity (as expressed by peak oxygen consumption <84% predicted) was decreased in 53% of patients (Stage I: 48%, Stages II–III: 52%, Stage IV: 78%); however, significant differences were noticed only between Stages I and IV (P=0.0025). Of note, significant correlations were found between peak oxygen consumption and DLCO (P=0.0083), minute ventilation (P<0.0001), oxygen pulse (P<0.0001), lactate threshold (P<0.0001), and peak ventilatory threshold (P<0.0001). CONCLUSION: CPET could be considered a useful tool in exercise intolerance evaluation in sarcoid patients with mild PFT abnormalities. Exercise limitation in sarcoidosis may be attributed to both ventilatory and cardiocirculatory impairment. Dove Medical Press 2015-08-18 /pmc/articles/PMC4547650/ /pubmed/26316723 http://dx.doi.org/10.2147/PPA.S86465 Text en © 2015 Kallianos et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kallianos, Anastasios Zarogoulidis, Paul Ampatzoglou, Fotini Trakada, Georgia Gialafos, Elias Pitsiou, Georgia Pataka, Athanasia Veletza, Lemonia Zarogoulidis, Konstantinos Hohenforst-Schmidt, Wolfgang Petridis, Dimitris Kioumis, Ioannis Rapti, Aggeliki Reduction of exercise capacity in sarcoidosis in relation to disease severity |
title | Reduction of exercise capacity in sarcoidosis in relation to disease severity |
title_full | Reduction of exercise capacity in sarcoidosis in relation to disease severity |
title_fullStr | Reduction of exercise capacity in sarcoidosis in relation to disease severity |
title_full_unstemmed | Reduction of exercise capacity in sarcoidosis in relation to disease severity |
title_short | Reduction of exercise capacity in sarcoidosis in relation to disease severity |
title_sort | reduction of exercise capacity in sarcoidosis in relation to disease severity |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547650/ https://www.ncbi.nlm.nih.gov/pubmed/26316723 http://dx.doi.org/10.2147/PPA.S86465 |
work_keys_str_mv | AT kallianosanastasios reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT zarogoulidispaul reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT ampatzogloufotini reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT trakadageorgia reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT gialafoselias reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT pitsiougeorgia reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT patakaathanasia reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT veletzalemonia reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT zarogoulidiskonstantinos reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT hohenforstschmidtwolfgang reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT petridisdimitris reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT kioumisioannis reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity AT raptiaggeliki reductionofexercisecapacityinsarcoidosisinrelationtodiseaseseverity |